Sectors

AMGN
Amgen Inc.
347.94
2 x 347.58
1 x 348.12
bid
ask
-
5.34
1.51%
2 @ 04:00 PM
347.51 -0.43 (0.12%)
Ytd 6.30%
1y 13.82%
345.87
day range
354.16
262.28
52 week range
388.16
Open 352.72 Prev Close 353.28 Low 345.87 High 354.16 Mkt Cap 187.56B
Vol 1.54M Avg Vol 2.83M EPS 14.23 P/E 24.45 Forward P/E 14.94
Beta 0.42 Short Ratio 6.07 Inst. Own 85.25% Dividend 10.08 Div Yield 2.85
Ex Div Date 05-15 Earning 04-30 50-d Avg 363.14 200-d Avg 319.22 1yr Est 350.55
Earning
Date For Estimate Reported Surprise surprise %
2026-05-07 2026-03 4.74 N/A N/A N/A
2026-02-03 2025-12 4.76 5.29 0.53 11.13%
2025-11-04 2025-09 5 5.64 0.64 12.80%
2025-08-05 2025-06 5.26 6.02 0.76 14.45%
2025-05-01 2025-03 4.16 4.9 0.74 17.79%
2025-02-04 2024-12 5.03 5.31 0.28 5.57%
Upgrade / Downgrade
Date Firm Action From To
2026-03-10 Jefferies Upgrade Hold
2026-02-20 Barclays Upgrade Equal-Weight
2026-02-19 Wells Fargo Upgrade Equal-Weight Equal-Weight
2026-02-18 Piper Sandler Upgrade Overweight Overweight
2026-02-12 Freedom Broker Downgrade Buy Hold
2026-02-06 Argus Research Upgrade Buy Buy
Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Insider Holder
Date Name Relation Quantity Description
2025-05-05 BRADNER JAMES E. Officer 29.75K Stock Award(Grant)
2026-03-03 BRADWAY ROBERT A Chief Executive Officer 672.64K Conversion of Exercise of derivative security
2025-05-22 ECKERT ROBERT ANDREW Director 25.03K Stock Award(Grant)
2026-03-02 GORDON MURDO Officer 56.81K Stock Award(Grant)
2026-03-02 GRAHAM JONATHAN P General Counsel 44.48K Stock Award(Grant)
2026-03-02 GRIFFITH PETER H. Chief Financial Officer 54.59K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 54.84M 19.08B 10.17%
2025-12-30 Blackrock Inc. 47.40M 16.49B 8.79%
2025-12-30 State Street Corporation 30.59M 10.64B 5.67%
2025-12-30 Capital World Investors 23.10M 8.04B 4.28%
2025-12-30 Capital International Investors 18.19M 6.33B 3.37%
2025-12-30 Morgan Stanley 15.74M 5.48B 2.92%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 16.93M 5.89B 3.14%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 13.58M 4.72B 2.52%
2026-01-30 Invesco QQQ Trust, Series 1 11.73M 4.08B 2.18%
2025-11-29 SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF 10.02M 3.49B 1.86%
2026-01-30 WASHINGTON MUTUAL INVESTORS FUND 9.79M 3.41B 1.82%
2026-01-30 Income Fund of America 7.45M 2.59B 1.38%
Dividend
Dividend Date
2.52 2026-05-15
2.52 2026-02-13
2.38 2025-11-21
2.38 2025-08-22
2.38 2025-05-16
2.38 2025-02-14
Split
Split Date
2 : 1 1999-11-22
2 : 1 1999-03-01
2 : 1 1995-08-16
3 : 1 1991-09-11
2 : 1 1990-08-13